Revolution in agricultural chemistry: How MustGrow Biologics is benefiting from the plight of Bayer and Corteva

Corteva Agriscience: Billion-dollar fever as a benchmark

A look at Corteva Agriscience shows how serious the situation is in agricultural chemistry. The US company, which emerged from the merger of Dow and DuPont, has recognized that organic growth in the biologicals sector is too slow to fill the regulatory gaps. The response was an aggressive shopping spree. With the acquisition of Stoller and Symborg for a reported total amount exceeding USD 1.5 billion, Corteva has impressively demonstrated the valuations that are now being demanded for functioning biological technologies.

These transactions have set a new price benchmark for the entire sector. Corteva is buying time and market share, but is under pressure to justify these high investments through scaling. For investors, the signal is clear: the market for biological crop protection has left its niche and become the primary driver of valuation multiples in the agricultural sector. It is no longer about "eco-romanticism," but about securing hard yields for farmers who would lose their crops without new resources.

MustGrow and Bayer: The technological accolade

While Corteva is buying, Bayer is relying on strategic partnerships to fill its pipeline – and has identified MustGrow Biologics as a key player. The challenge with biological agents has often been their lack of effectiveness compared to "chemical weapons." MustGrow has solved this problem with its patented mustard plant-based technology, which achieves 100% effectiveness compared to synthetic standards, as confirmed by laboratory tests.

This convinced Bayer. The Leverkusen-based giant has signed an exclusive agreement with MustGrow for soil applications in Europe, the Middle East, and Africa. This deal is tantamount to a technological and commercial accolade, as Bayer does not lend its global distribution channels and brand to experimental gimmicks, but only to products that work on an industrial scale. For MustGrow, this means that its technology has arrived in the engine room of the market leader without the small company having to shoulder the enormous costs of global distribution itself.

MustGrow as a supplier to the big players in the organic boom

MustGrow's business model differs fundamentally from that of a traditional producer. The Company relies on a "capital light model" that focuses on licenses and royalties. Instead of investing billions in its own factories, MustGrow supplies the intellectual property and the active ingredient, while partners such as Bayer or Sumitomo Corporation take care of marketing.

This results in an exciting constellation for investors. MustGrow's stock is not yet valued at the multiples that are customary for acquisitions in the sector. At the same time, the technological risk has been massively reduced by the validation of the partners, as companies such as Bayer have virtually taken over the due diligence for the shareholders. MustGrow is therefore more than a bet on the future; it is direct access to a key technology for agricultural change. The stock has not shown much momentum so far. The industry attributes this to the Company's still low profile. With a partner like Bayer behind it and the good conscience that MustGrow's products preserve soils and make agriculture a generational project again, the Company should soon receive more attention.

Conclusion: Validated technology meets market demand

The trend in 2026 is clear: the big players need to position themselves as greener and more sustainable, and they are willing to pay high prices to do so. MustGrow Biologics is right at the intersection of this demand, equipped with partnerships that have already validated its business model. While Corteva and Bayer have to turn their huge tankers around in the current market phase, MustGrow, as an agile speedboat, can benefit directly from every license agreement despite the remaining risks typical for the current stage. The stock thus offers a rare combination of the security of established partnerships and the leverage of a specialized technology provider. It is a stock to watch for speculatively oriented investors.